Biodesix (NASDAQ:BDSX) Stock Price Breaks Below 200-Day Moving Average – Here’s What Happened

Shares of Biodesix, Inc. (NASDAQ:BDSX) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $18.90 and traded as low as $7.96. Biodesix shares last traded at $8.53, with a volume of 1,586,239 shares trading hands.

More Biodesix News

Here are the key news stories impacting Biodesix this week:

• Neutral Sentiment: Biodesix plans to end 2026 with approximately 115 sales representatives, an effort to expand its commercial reach. Article
• Negative Sentiment: Third-quarter revenue was $24.04 million, below analysts’ estimate of $27.49 million. Biodesix reported a loss of $0.75 per share; one cited consensus was $0.75, while Zacks reported a $0.74 estimate. Article
• Negative Sentiment: For 2026, the company forecast revenue of $101 million to $103 million, below the $111.7 million analyst consensus—signaling a weaker outlook than investors had expected. Article
• Negative Sentiment: Biodesix disclosed the departure of Chief Commercial Officer Ki…; the leadership change may add uncertainty as the company works to grow sales. Article
• Negative Sentiment: Following the sharp decline, Johnson Fistel said it had opened an investigation into whether Biodesix or its officers made misleading statements or failed to disclose material information. This is an investigation, not a finding of wrongdoing. Article

Wall Street Analyst Weigh In

A number of research firms have commented on BDSX. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 8th. TD Cowen reissued a “buy” rating and set a $40.00 price objective (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. HC Wainwright reissued a “buy” rating on shares of Biodesix in a report on Thursday, October 22nd. Finally, Canaccord Genuity Group increased their price target on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Biodesix currently has an average rating of “Moderate Buy” and an average target price of $36.25.

Biodesix Stock Down 57.0%

The company has a debt-to-equity ratio of 5.12, a current ratio of 2.85 and a quick ratio of 2.85. The firm has a 50-day moving average of $25.53 and a 200 day moving average of $18.90. The stock has a market capitalization of $89.99 million, a price-to-earnings ratio of -3.09 and a beta of 0.65.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.75) earnings per share for the quarter, meeting the consensus estimate of ($0.75). The company had revenue of $24.04 million during the quarter, compared to analysts’ expectations of $27.49 million. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. As a group, sell-side analysts forecast that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Biodesix news, Director Jack Schuler acquired 15,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average cost of $24.47 per share, for a total transaction of $367,050.00. Following the completion of the purchase, the director owned 555,810 shares in the company, valued at approximately $13,600,670.70. This trade represents a 2.77% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have acquired a total of 42,600 shares of company stock worth $1,033,062 in the last three months. 23.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BDSX. Allworth Financial LP bought a new position in Biodesix in the second quarter worth about $112,000. Walleye Capital LLC acquired a new position in Biodesix in the 1st quarter valued at $157,000. Renaissance Technologies LLC acquired a new stake in Biodesix during the 1st quarter worth approximately $173,000. Cetera Investment Advisers grew its stake in Biodesix by 20.0% in the first quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock valued at $174,000 after acquiring an additional 2,000 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of Biodesix in the second quarter valued at $354,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.